ArticlePLoS computational biology2016
Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis.
Article in PLoS computational biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- Natural Alkaloids as Antiviral Agents Against RNA Viruses: A Comprehensive and Mechanistic Review.Molecules (Basel, Switzerland) · 2026Review
- AΙ-Driven Drug Repurposing: Applications and Challenges.Medicines (Basel, Switzerland) · 2025Review
- Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy.Toxics · 2024Review
- Transcriptome-based deep learning analysis identifies drug candidates targeting protein synthesis and autophagy for the treatment of muscle wasting disorder.Experimental & molecular medicine · 2024Article
- Bioinformatic-based Study to Investigate the Structure and Function of Pro-inflammatory Cytokines TNFα and IL-6 Involved in the Pathogenesis of COVID-19.Iranian journal of pathology · 2024Article
- A Yeast BiFC-seq Method for Genome-wide Interactome Mapping.Genomics, proteomics & bioinformatics · 2022Article
- A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.Research square · 2022Article
- SperoPredictor: An Integrated Machine Learning and Molecular Docking-Based Drug Repurposing Framework With Use Case of COVID-19.Frontiers in public health · 2022Article
- Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation.Future virology · 2021Article
- Identification of Cross-Pathway Connections via Protein-Protein Interactions Linked to Altered States of Metabolic Enzymes in Cervical Cancer.Frontiers in medicine · 2021Article
- Artificial intelligence in COVID-19 drug repurposing.The Lancet. Digital health · 2020Review
- Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020Review
- Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.Journal of proteome research · 2020Article
- A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19.PLoS biology · 2020Observational
- A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19.ChemRxiv : the preprint server for chemistry · 2020Article
- Shotgun drug repurposing biotechnology to tackle epidemics and pandemics.Drug discovery today · 2020Article
- Shotgun drug repurposing biotechnology to tackle epidemics and pandemics.ChemRxiv : the preprint server for chemistry · 2020Article
- In Silico Discovery of Candidate Drugs against Covid-19.Viruses · 2020Article
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.Cell discovery · 2020Article
- Systems Biology Approaches to Understanding the Human Immune System.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Viruses require host cellular factors for successful replication. A comprehensive systems-level investigation of the virus-host interactome is critical for understanding the roles of host factors with the end goal of discovering new druggable antiviral targets. Gene-trap insertional mutagenesis is a high-throughput forward genetics approach to randomly disrupt (trap) host genes and discover host genes that are essential for viral replication, but not for host cell survival. In this study, we used libraries of randomly mutagenized cells to discover cellular genes that are essential for the replication of 10 distinct cytotoxic mammalian viruses, 1 gram-negative bacterium, and 5 toxins. We herein reported 712 candidate cellular genes, characterizing distinct topological network and evolutionary signatures, and occupying central hubs in the human interactome. Cell cycle phase-specific network analysis showed that host cell cycle programs played critical roles during viral replication (e.g. MYC and TAF4 regulating G0/1 phase). Moreover, the viral perturbation of host cellular networks reflected disease etiology in that host genes (e.g. CTCF, RHOA, and CDKN1B) identified were frequently essential and significantly associated with Mendelian and orphan diseases, or somatic mutations in cancer. Computational drug repositioning framework via incorporating drug-gene signatures from the Connectivity Map into the virus-host interactome identified 110 putative druggable antiviral targets and prioritized several existing drugs (e.g. ajmaline) that may be potential for antiviral indication (e.g. anti-Ebola). In summary, this work provides a powerful methodology with a tight integration of gene-trap insertional mutagenesis testing and systems biology to identify new antiviral targets and drugs for the development of broadly acting and targeted clinical antiviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.